Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+ ...

The following is a summary of “Association between the triglyceride-glucose index and liver fibrosis in adults with ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

Among the general US population, simple and affordable non-invasive liver fibrosis scoring systems may be able to identify individuals at risk for HF.

Study Finds Targeting Inflammation May Not Help Reduce Liver Fibrosis in MAFLD July 26, 2024 — Researchers uncovered new information about the role inflammation plays in mitigating liver ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

Kevin Dwyer, a cystic fibrosis patient, had to enlist a team of lawyers and share his story on the Today Show to gain ...

The liver can regenerate itself, but there are factors that make self-repair impossible. Find out what they are here.

In a series of studies at McMaster, Dr. Schertzer’s research group demonstrated that treatment with QBECO SSI resulted in a marked reduction in liver fat, inflammation, and fibrosis in fatty liver ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today ...

Although metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed to replace the diagnosis of non-alcoholic fatty liver disease (NAFLD) with new diagnostic criteria since ...